

Supplementary appendix

Table of contents

Supplementary Table 1—SGLT2i use at different time points during the FIDELIO-DKD and FIGARO-DKD studies.....	2
Supplementary Table 2 —Time from SGLT2i initiation to randomization during the FIDELIO-DKD and FIGARO-DKD studies	3
Supplementary Table 3—Baseline characteristics in patients receiving/not receiving SGLT2is at baseline.....	4
Supplementary Table 4—Use of potassium-lowering agents at different time points during the FIDELIO-DKD and FIGARO-DKD studies	10
Supplementary Figure 1—Percentage of time under co-medication with an SGLT2i during the studies.....	18
Supplementary Figure 2—Chronic eGFR slope over time in patients receiving/not receiving an SGLT2i at baseline	19
Supplementary Figure 3—Systolic blood pressure over time in patients A) receiving, and B) not receiving an SGLT2i at baseline	20

Supplementary Table 1—SGLT2i use at different time points during the FIDELIO-DKD and FIGARO-DKD studies

	Finerenone (<i>n</i> = 6,519)	Placebo (<i>n</i> = 6,507)	Total (<i>N</i> = 13,026)
Received SGLT2i at any time during the on-treatment period	958 (14.7)	1,032 (15.9)	1,990 (15.3)
SGLT2i use at baseline	438 (6.7)	439 (6.7)	877 (6.7)
Initiation of SGLT2i use during the on-treatment period	520 (8.0)	593 (9.1)	1,113 (8.5)
No SGLT2i use at any time during the on-treatment period	5,561 (85.3)	5,475 (84.1)	11,036 (84.7)

Data are *n* (%). The on-treatment period was defined as from randomization up until the on-treatment period censoring date. SGLT2i, sodium–glucose cotransporter 2 inhibitor.

Supplementary Table 2 —Time from SGLT2i initiation to randomization during the FIDELIO-DKD and FIGARO-DKD studies

Time from SGLT2i start to randomization, n (%)	Finerenone (<i>n</i> = 438)	Placebo (<i>n</i> = 439)	Total (<i>N</i> = 877)
≤1 month	38 (8.7)	34 (7.7)	72 (8.2)
>1 month to ≤2 months	40 (9.1)	34 (7.7)	74 (8.4)
>2 months to ≤3 months	28 (6.4)	44 (10.0)	72 (8.2)
>3 months to ≤4 months	36 (8.2)	32 (7.3)	68 (7.8)
>4 months to ≤5 months	22 (5.0)	26 (5.9)	48 (5.5)
>5 months to ≤6 months	20 (4.6)	17 (3.9)	37 (4.2)
>6 months	254 (58.0)	252 (57.4)	506 (57.7)

SGLT2i, sodium–glucose cotransporter 2 inhibitor.

Supplementary Table 3—Baseline characteristics in patients receiving/not receiving SGLT2is at baseline

	SGLT2i at baseline		No SGLT2i at baseline	
	Finerenone (<i>n</i> = 438)	Placebo (<i>n</i> = 439)	Finerenone (<i>n</i> = 6,081)	Placebo (<i>n</i> = 6,068)
Age, years	61.8 ± 9.7	61.7 ± 9.6	64.9 ± 9.3	65.0 ± 9.6
Sex	331 (75.6)	340 (77.4)	4,150 (68.2)	4,267 (70.3)
Male	331 (75.6)	340 (77.4)	4,150 (68.2)	4,267 (70.3)
Female	107 (24.4)	99 (22.6)	1,931 (31.8)	1,801 (29.7)
World region				
North America	65 (14.8)	83 (18.9)	961 (15.8)	942 (15.5)
Latin America	41 (9.4)	28 (6.4)	678 (11.1)	687 (11.3)
Western Europe	126 (28.8)	118 (26.9)	1,218 (20.0)	1,274 (21.0)

Eastern Europe	51 (11.6)	56 (12.8)	1,541 (25.3)	1,478 (24.4)
Asia	133 (30.4)	133 (30.3)	1,467 (24.1)	1,471 (24.2)
Other	22 (5.0)	21 (4.8)	216 (3.6)	216 (3.6)
Race				
White	325 (74.2)	319 (72.2)	4,124 (67.8)	4,101 (67.6)
Asian	92 (21.0)	93 (21.2)	1,340 (22.0)	1,369 (22.6)
Black/African American	5 (1.1)	15 (3.4)	248 (4.1)	254 (4.2)
Systolic blood pressure, mmHg	133.3 ± 14.8	133.4 ± 14.0	137.0 ± 14.1	137.0 ± 14.3
Diastolic blood pressure, mmHg	75.5 ± 9.6	76.4 ± 9.7	76.4 ± 9.6	76.4 ± 9.6
BMI, kg/m ²	32.8 ± 6.3	32.3 ± 5.8	31.2 ± 6.0	31.2 ± 6.0
Duration of diabetes, years	16.0 ± 8.4	15.1 ± 7.7	15.4 ± 8.8	15.4 ± 8.7
HbA _{1c} , % (mmol/mol)	7.94 ± 1.22 (63.3 ± 13.3)	7.98 ± 1.23 (63.7 ± 13.4)	7.69 ± 1.37 (60.6 ± 15.0)	7.67 ± 1.36 (60.3 ± 14.9)

Serum potassium, mEq/L	4.28 ± 0.42	4.31 ± 0.41	4.35 ± 0.44	4.35 ± 0.45
eGFR, mL/min/1.73 m ²				
Mean	66.8 ± 21.2	65.7 ± 21.0	56.8 ± 21.5	57.1 ± 21.7
Distribution				
<25	0	0	81 (1.3)	81 (1.3)
25–<45	72 (16.4)	70 (15.9)	2,045 (33.6)	2,045 (33.7)
45–<60	109 (24.9)	132 (30.1)	1,608 (26.4)	1,585 (26.1)
≥60	257 (58.7)	237 (54.0)	2,346 (38.6)	2,355 (38.8)
UACR, mg/g				
Median	445 (185–959)	448 (185–933)	520 (198–1,146)	521 (200–1,180)
Distribution				
<30	7 (1.6)	9 (2.1)	113 (1.9)	101 (1.7)

30–<300	141 (32.2)	142 (32.3)	1,935 (31.8)	1,881 (31.0)
≥300	290 (66.2)	288 (65.6)	4,031 (66.3)	4,083 (67.3)
Waist–hip ratio	1.02 ± 0.09	1.03 ± 0.13	1.00 ± 0.11	1.00 ± 0.11
Waist circumference, cm	111.4 ± 14.8	110.8 ± 14.9	106.6 ± 15.1	106.8 ± 15.1
hs-C-reactive protein, mg/L	2.24 (1.07–4.89)	2.21 (1.08–4.64)	2.20 (0.94–5.19)	2.22 (0.95–5.12)
Heart rate, bpm	74.6 ± 11.4	75.3 ± 11.9	73.1 ± 11.4	72.8 ± 11.4
History of cardiovascular disease	194 (44.3)	211 (48.1)	2,785 (45.8)	2,745 (45.2)
History of heart failure	25 (5.7)	21 (4.8)	460 (7.6)	501 (8.3)
Current smoker	80 (18.3)	82 (18.7)	985 (16.2)	946 (15.6)
Medication use at baseline				
RAS inhibitor	437 (99.8)	438 (99.8)	6,071 (99.8)	6,057 (99.8)
Beta-blocker	216 (49.3)	216 (49.2)	3,020 (49.7)	3,052 (50.3)

Diuretic	224 (51.1)	215 (49.0)	3,101 (51.0)	3,170 (52.2)
Loop	72 (16.4)	77 (17.5)	1,310 (21.5)	1,344 (22.1)
Thiazide	127 (29.0)	122 (27.8)	1,482 (24.4)	1,421 (23.4)
Statin	363 (82.9)	374 (85.2)	4,294 (70.6)	4,368 (72.0)
Potassium supplement	10 (2.3)	14 (3.2)	186 (3.1)	175 (2.9)
Potassium-lowering agent	5 (1.1)	2 (0.5)	89 (1.5)	86 (1.4)
Glucose-lowering therapies				
Insulin and analogues	264 (60.3)	251 (57.2)	3,602 (59.2)	3,513 (57.9)
Metformin	352 (80.4)	340 (77.4)	3,460 (56.9)	3,405 (56.1)
Sulfonylurea	120 (27.4)	98 (22.3)	1,571 (25.8)	1,600 (26.4)
DPP-4 inhibitor	137 (31.3)	119 (27.1)	1,523 (25.0)	1,499 (24.7)
GLP-1RA	86 (19.6)	81 (18.5)	411 (6.8)	366 (6.0)

Alpha glucosidase inhibitor	25 (5.7)	10 (2.3)	298 (4.9)	323 (5.3)
Meglitinide	16 (3.7)	13 (3.0)	257 (4.2)	245 (4.0)
Thiazolidinedione	33 (7.5)	25 (5.7)	235 (3.9)	224 (3.7)

Data are mean \pm standard deviation, *n* (%), or median (interquartile range). bpm, beats per minute; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonist; hs, high sensitivity; RAS, renin–angiotensin system; SGLT2i, sodium–glucose cotransporter 2 inhibitor; UACR, urine albumin-to-creatinine ratio.

Supplementary Table 4—Use of potassium-lowering agents at different time points during the FIDELIO-DKD and FIGARO-DKD studies

n (%)	Finerenone (n = 6,519)	Placebo (n = 6,507)	Total (N = 13,026)
Received potassium-lowering agent at any time during the on-treatment period	324 (5.0)	217 (3.3)	541 (4.2)
Calcium polystyrene sulfonate	178 (2.7)	122 (1.9)	300 (2.3)
Sodium polystyrene sulfonate	140 (2.1)	96 (1.5)	236 (1.8)
Sodium zirconium cyclosilicate	7 (0.1)	3 (<0.1)	10 (<0.1)
Patiomer or patiomer sorbitex calcium	15 (0.2)	7 (0.1)	22 (0.2)
Potassium-lowering agent use at baseline	94 (1.4)	88 (1.4)	182 (1.4)
Calcium polystyrene sulfonate	67 (1.0)	53 (0.8)	120 (0.9)
Sodium polystyrene sulfonate	30 (0.5)	32 (0.5)	62 (0.5)
Sodium zirconium cyclosilicate	0	1 (<0.1)	1 (<0.1)
Patiomer or patiomer sorbitex calcium	2 (<0.1)	4 (0.1)	6 (<0.1)
Initiation of potassium-lowering agent use during the on-treatment period	230 (3.5)	129 (2.0)	359 (2.8)

No potassium-lowering agent use at any time during the on-treatment period	6,195 (95.0)	6,290 (96.7)	12,485 (95.8)
----------------------------------------------------------------------------	--------------	--------------	---------------

Multiple drug groups per drug are possible, therefore the same drug may be counted in more than one category for the same patient.

Supplementary Table 5—Baseline characteristics in patients initiating SGLT2i use during the on-treatment period

	No SGLT2i at baseline; with SGLT2i initiation during the on-treatment period		No SGLT2i at baseline; without SGLT2i initiation during the on-treatment period	
	Finerenone (<i>n</i> = 520)	Placebo (<i>n</i> = 593)	Finerenone (<i>n</i> = 5,561)	Placebo (<i>n</i> = 5,475)
Age, years	62.6 ± 9.3	62.4 ± 9.6	65.1 ± 9.3	65.3 ± 9.6
Sex				
Male	392 (75.4)	458 (77.2)	3,758 (67.6)	3,809 (69.6)
Female	128 (24.6)	135 (22.8)	1,803 (32.4)	1,666 (30.4)
World region				
North America	50 (9.6)	62 (10.5)	911 (16.4)	880 (16.1)
Latin America	54 (10.4)	53 (8.9)	624 (11.2)	634 (11.6)

Western Europe	143 (27.5)	179 (30.2)	1,075 (19.3)	1,095 (20.0)
Eastern Europe	46 (8.8)	45 (7.6)	1,495 (26.9)	1,433 (26.2)
Asia	219 (42.1)	244 (41.1)	1,248 (22.4)	1,227 (22.4)
Other	8 (1.5)	10 (1.7)	208 (3.7)	206 (3.8)
Race				
White	305 (58.7)	344 (58.0)	3,819 (68.7)	3,757 (68.6)
Asian	186 (35.8)	212 (35.8)	1,154 (20.8)	1,157 (21.1)
Black/African American	8 (1.5)	10 (1.7)	240 (4.3)	244 (4.5)
Systolic blood pressure, mmHg	137.4 ± 14.2	137.1 ± 14.9	137.0 ± 14.1	137.0 ± 14.2
Diastolic blood pressure, mmHg	77.3 ± 10.0	77.2 ± 9.8	76.3 ± 9.6	76.3 ± 9.6
BMI, kg/m ²	31.1 ± 5.8	31.2 ± 5.7	31.2 ± 6.0	31.2 ± 6.0
Duration of diabetes, years	15.1 ± 8.0	15.1 ± 8.1	15.4 ± 8.8	15.4 ± 8.8

HbA _{1c} , % (mmol/mol)	7.99 ± 1.35 (63.8 ± 14.7)	7.96 ± 1.32 (63.5 ± 14.4)	7.67 ± 1.37 (60.3 ± 15.0)	7.64 ± 1.36 (60.0 ± 14.9)
Serum potassium, mEq/L	4.27 ± 0.42	4.31 ± 0.41	4.36 ± 0.44	4.36 ± 0.45
eGFR, mL/min/1.73 m ²				
Mean	66.2 ± 20.9	66.0 ± 21.1	56.0 ± 21.3	56.1 ± 21.5
Distribution				
<25	2 (0.4)	1 (0.2)	79 (1.4)	80 (1.5)
25–<45	76 (14.6)	103 (17.4)	1,969 (35.4)	1,942 (35.5)
45–<60	143 (27.5)	149 (25.1)	1,465 (26.3)	1,436 (26.2)
≥60	299 (57.5)	340 (57.3)	2,047 (36.8)	2,015 (36.8)
UACR, mg/g				
Median	423 (155–818)	481 (178–1,014)	531 (205–1,172)	526 (204–1,202)
Distribution				


<30	7 (1.3)	10 (1.7)	106 (1.9)	91 (1.7)
30–<300	197 (37.9)	205 (34.6)	1,738 (31.3)	1,676 (30.6)
≥300	316 (60.8)	377 (63.6)	3,715 (66.8)	3,706 (67.7)
Waist–hip ratio	1.01 ± 0.10	1.01 ± 0.09	1.00 ± 0.11	1.00 ± 0.11
Waist circumference, cm	107.4 ± 14.5	107.2 ± 14.3	106.6 ± 15.2	106.8 ± 15.1
hs-C-reactive protein, mg/L	1.74 (0.73–3.91)	1.97 (0.85–4.19)	2.24 (0.95–5.30)	2.25 (0.96–5.18)
Heart rate, bpm	75.2 ± 11.6	74.5 ± 11.8	72.9 ± 11.4	72.6 ± 11.4
History of cardiovascular disease	213 (41.0)	222 (37.4)	2,572 (46.3)	2,523 (46.1)
History of heart failure	22 (4.2)	30 (5.1)	438 (7.9)	471 (8.6)
Current smoker	111 (21.3)	110 (18.5)	874 (15.7)	836 (15.3)
Medication use at baseline				
RAS inhibitor	519 (99.8)	592 (99.8)	5,552 (99.8)	5,465 (99.8)

Beta-blocker	232 (44.6)	272 (45.9)	2,788 (50.1)	2,780 (50.8)
Diuretic	241 (46.3)	282 (47.6)	2,860 (51.4)	2,888 (52.7)
Loop	76 (14.6)	89 (15.0)	1,234 (22.2)	1,255 (22.9)
Thiazide	151 (29.0)	161 (27.2)	1,331 (23.9)	1,260 (23.0)
Statin	395 (76.0)	448 (75.5)	3,899 (70.1)	3,920 (71.6)
Potassium supplement	9 (1.7)	10 (1.7)	177 (3.2)	165 (3.0)
Potassium-lowering agent	7 (1.3)	6 (1.0)	82 (1.5)	80 (1.5)
Glucose-lowering therapies	510 (98.1)	588 (99.2)	5,406 (97.2)	5,339 (97.5)
Insulin and analogues	282 (54.2)	332 (56.0)	3,320 (59.7)	3,181 (58.1)
Metformin	406 (78.1)	434 (73.2)	3,054 (54.9)	2,971 (54.3)
Sulfonylurea	156 (30.0)	177 (29.8)	1,415 (25.4)	1,423 (26.0)
DPP-4 inhibitor	205 (39.4)	233 (39.3)	1,318 (23.7)	1,266 (23.1)

GLP-1RA	75 (14.4)	66 (11.1)	336 (6.0)	300 (5.5)
Alpha glucosidase inhibitor	32 (6.2)	56 (9.4)	266 (4.8)	267 (4.9)
Meglitinide	25 (4.8)	35 (5.9)	232 (4.2)	210 (3.8)
Thiazolidinedione	38 (7.3)	34 (5.7)	197 (3.5)	190 (3.5)


Data are mean \pm standard deviation, *n* (%), or median (interquartile range). bpm, beats per minute; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonist; hs, high sensitivity; RAS, renin–angiotensin system; SGLT2i, sodium–glucose cotransporter 2 inhibitor; UACR, urine albumin-to-creatinine ratio.

Supplementary Figure 1—Percentage of time under co-medication with an SGLT2i during the studies





Data are co-medication use from day of randomization until on-treatment analysis censoring date. SGLT2i, sodium–glucose cotransporter 2 inhibitor.

Supplementary Figure 2—Chronic eGFR slope over time in patients receiving/not receiving an SGLT2i at baseline



Chronic eGFR slope (and 95% CI) from month 4 to the end-of-study visit. CI, confidence interval; eGFR, estimated glomerular filtration rate; LS, least-squares; SGLT2i, sodium–glucose cotransporter 2 inhibitor.

Supplementary Figure 3—Systolic blood pressure over time in patients A) receiving, and B) not receiving an SGLT2i at baseline



SBP, systolic blood pressure; SGLT2i, sodium–glucose cotransporter 2 inhibitor.